Scientific article
OA Policy
English

Hairy cell leukemia: a specific 17-gene expression signature points to new targets for therapy

Published inJournal of cancer research and clinical oncology, vol. 148, no. 8, p. 2013-2022
Publication date2022-08
First online date2022-04-27
Abstract

Background: Hairy cell leukemia (HCL) is a rare chronic B cell malignancy, characterized by infiltration of bone marrow, blood and spleen by typical "hairy cells" that bear the BRAFV600E mutation. However, in addition to the intrinsic activation of the MAP kinase pathway as a consequence of the BRAFV600E mutation, the potential participation of other signaling pathways to the pathophysiology of the disease remains unclear as the precise origin of the malignant hairy B cells.

Materials and methods: Using mRNA gene expression profiling based on the Nanostring technology and the analysis of 290 genes with crucial roles in B cell lymphomas, we defined a 17 gene expression signature specific for HCL.

Results: Separate analysis of samples from classical and variant forms of hairy cell leukemia showed almost similar mRNA expression profiles apart from overexpression in vHCL of the immune checkpoints CD274 and PDCD1LG2 and underexpression of FAS. Our results point to a post-germinal memory B cell origin and in some samples to the activation of the non-canonical NF-κB pathway.

Conclusions: This study provides a better understanding of the pathogenesis of HCL and describes new and potential targets for treatment approaches and guidance for studies in the molecular mechanisms of HCL.

Keywords
  • EBI3
  • Gene expression
  • Hairy cell leukemia
  • NF-KB pathway
  • RGS13
  • B-Lymphocytes / pathology
  • Humans
  • Leukemia, Hairy Cell / drug therapy
  • Leukemia, Hairy Cell / genetics
  • Leukemia, Hairy Cell / metabolism
  • Proto-Oncogene Proteins B-raf / genetics
  • Proto-Oncogene Proteins B-raf / metabolism
  • RNA, Messenger
  • Transcriptome
Citation (ISO format)
MAITRE, Elsa et al. Hairy cell leukemia: a specific 17-gene expression signature points to new targets for therapy. In: Journal of cancer research and clinical oncology, 2022, vol. 148, n° 8, p. 2013–2022. doi: 10.1007/s00432-022-04010-4
Main files (1)
Article (Published version)
Secondary files (7)
Appendix
accessLevelPublic
Appendix
accessLevelPublic
Appendix
accessLevelPublic
Show more
Identifiers
Journal ISSN0171-5216
184views
220downloads

Technical informations

Creation27/01/2023 09:20:00
First validation27/01/2023 09:20:00
Update16/03/2023 10:32:33
Status update16/03/2023 10:32:29
Last indexation01/11/2024 04:04:44
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack